Eli Lilly's weight loss treatment Zepbound might be a blockbuster in the making, but it wasn't without its challenges. See ...

Eli Lilly (LLY) inks licensing deal with EVA Pharma to expand access to its JAK inhibitor Olumiant (baricitinib) in Africa.

Groups including Hims & Hers and Ro benefiting from shortages of blockbuster anti-obesity jabs could find revenue streams ...

Eli Lilly and Company (LLY) and EVA Pharma Wednesday announced partnership to expand access to baricitinib to people in 49 low- to ...

Eli Lilly and Company (NYSE: LLY) and EVA Pharma announced today that the companies have entered into an agreement to expand ...

Eli Lilly and Egypt's EVA Pharma have entered into an agreement to license Lilly's rheumatoid arthritis drug in 49 countries in Africa, the companies said on Wednesday.

Shares of Nvidia slid 9.5% on Wall Street on Tuesday amid a broader market selloff, erasing $278.9 billion from the company's market value. That was the biggest one-day market cap decline on record ...

In 2022, the global oncology market was valued at approximately $203.42 billion and is expected to reach over $470.61 billion ...

We recently published a list of 10 Stocks That May Be Splitting Soon. In this article, we are going to take a look at where ...

The Richmond, California-based company will be one of several biotech firms to list shares this year. Rate-cut expectations ...

Here’s why older internet celebs — granfluencers — soon might be making rounds on the Alzheimer's drug marketing scene.

Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a ...